Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafasitamab + lenalidomide + rituximab
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Tafasitamab + lenalidomide + rituximab is a three-drug combination regimen approved for the treatment of adults with relapsed or refractory follicular lymphoma. Tafasitamab is a humanized Fc-modified monoclonal antibody targeting CD19 on B cells, exerting direct cytotoxicity and enhancing immune-mediated cell killing. Lenalidomide is an immunomodulatory agent that can enhance T and NK cell function and has antiangiogenic and direct antineoplastic properties. Rituximab is a chimeric monoclonal antibody targeting CD20, leading to B cell depletion via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis. This combination leverages dual targeting of CD19 and CD20 antigens on B cells and immune modulation, resulting in improved progression-free survival in follicular lymphoma compared with lenalidomide and rituximab alone. The combination was approved by the FDA in 2025 and is supported by phase 3 trial evidence[1][2][3][5][7].
- Other names
- tafasitamab + rituximab + lenalidomide
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)
Beyond the preview
Go deeper on tafasitamab + lenalidomide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafasitamab + lenalidomide + rituximab.